🇺🇸 Oxybutynin Transdermal Patch in United States

13 US adverse-event reports

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

Most-reported reactions

  1. Condition Aggravated — 2 reports (15.38%)
  2. Muscular Weakness — 2 reports (15.38%)
  3. Pain — 2 reports (15.38%)
  4. Angioneurotic Oedema — 1 report (7.69%)
  5. Aortic Stenosis — 1 report (7.69%)
  6. Atrial Fibrillation — 1 report (7.69%)
  7. Breast Cancer Metastatic — 1 report (7.69%)
  8. Cardiac Failure — 1 report (7.69%)
  9. Chest Pain — 1 report (7.69%)
  10. Coronary Artery Disease — 1 report (7.69%)

Source database →

Other Urology / Neurology approved in United States

Frequently asked questions

Is Oxybutynin Transdermal Patch approved in United States?

Oxybutynin Transdermal Patch does not currently have US marketing authorisation in our dataset.

Who is the marketing authorisation holder for Oxybutynin Transdermal Patch in United States?

University of California, Davis is the originator. The local marketing authorisation holder may differ — check the official source linked above.